COMMUNIQUÉS West-GlobeNewswire

New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
06/02/2019
Once-daily IV-to-oral NUZYRA safe and effective in adults with pneumonia and skin infections, demonstrating clinical activity against relevant pneumonia- and skin-associated drug resistant bacteria BOSTON, Feb. 06, 2019 [...]
LeMaitre Vascular Will Announce Fourth Quarter 2018 Earnings Results on February 19, 2019
06/02/2019
BURLINGTON, Mass., Feb. 06, 2019 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2018 financial results on Tuesday, February 19, 2019, after the market [...]
RavenQuest and Bonify Announce One-Year Extension of Services Agreement
06/02/2019
VANCOUVER, British Columbia, Feb. 06, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT) announces that RavenQuest will continue to provide [...]
The Ensign Group Reports Fourth Quarter and Fiscal Year 2018 Results
06/02/2019
Conference Call and Webcast scheduled for tomorrow, February 7, 2019 at 10:00 am PT MISSION VIEJO, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group [...]
HealthEquity Reports Year-End Sales Metrics
06/02/2019
Custodial Assets of $8.1 billion, up 19% year-over-year, HSA Members up 17% DRAPER, Utah, Feb. 06, 2019 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), one of the nation's largest [...]
Misonix Fiscal 2019 Second Quarter Revenue Rises 22% to a Record $10.2 Million
06/02/2019
FARMINGDALE, N.Y., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, [...]
Conformis Reports Fourth Quarter and Year Ended 2018 Financial Results
06/02/2019
BILLERICA, Mass., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell [...]
Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director
06/02/2019
Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director Notes the resignation of Christian Mulliez as [...]
Le Conseil d'administration de Sanofi prend acte de la démission de Christian Mulliez et coopte Christophe Babule en tant que nouvel administrateur
06/02/2019
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NASDAQ : SNY) Le Conseil d'administration de Sanofi prend acte de la démission de Christian Mulliez et coopte Christophe Babule en tant que nouvel administrateur [...]
OraSure Announces 2018 Full Year and Fourth Quarter Financial Results
06/02/2019
BETHLEHEM, Pa., Feb. 06, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its financial results for the full [...]
Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Date
06/02/2019
BATON ROUGE, La., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the fourth quarter and year ended December 31, 2018, after the market closes on February [...]
Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
06/02/2019
FDA approves Cablivi ® (caplacizumab-yhdp), the first Nanobody ® -based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP) First medicine approved in the U.S. specifically for the treatment of [...]
Sanofi : La FDA approuve Cablivi® (caplacizumab-yhdp), le premier médicament à base de Nanobody® pour le traitement du purpura thrombotique thrombocytopénique (PTT) acquis de l'adulte
06/02/2019
La FDA approuve Cablivi ® (caplacizumab-yhdp), le premier médicament à base de Nanobody ® pour le traitement du purpura thrombotique thrombocytopénique (PTT) acquis de l'adulte Premier médicament spécifiquement approuvé [...]
Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2019
06/02/2019
LYON, France, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – 31 Janvier 2019
06/02/2019
LYON, France, 06 févr. 2019 (GLOBE NEWSWIRE) -- Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Lyon - France Places de cotation : Euronext Paris de Euronext (Compartiment C - Code ISIN : [...]
The Centers for Medicare & Medicaid Services (CMS) Grants Alpha II Status as 2019 Qualified Registry
06/02/2019
Alpha II’s integrated, web-based registry service received status as a CMS qualified registry for sixth consecutive year TALLAHASSEE, Fla., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Alpha II, LLC , a leading developer of [...]
Tauriga Sciences Inc. Showcases its Graphic Design and Artwork for the Retail Display Box of its CBD Infused Gum
06/02/2019
New York, NY, Feb. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG ) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and [...]
ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2018
06/02/2019
Conference Call Scheduled for Thursday, February 14, 2019 at 9:00 AM ET PORTLAND, Maine, Feb. 06, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health [...]
Sol-Gel Technologies Announces FDA Approval for Perrigo’s Generic Acyclovir Cream, 5%
06/02/2019
Sol-Gel and Perrigo will equally share the gross profits generated from sales of the product NESS ZIONA, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a [...]

Pages